Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ZMYM4 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | BEND5 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | PARP1 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
mRNA | CEP162 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-07 |
mRNA | SERINC3 | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-07 |
mRNA | ZMYM3 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | FAM193A | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | USP37 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | ATP6V1G2-DDX39B | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | TPR | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-07 |